[go: up one dir, main page]

MX2009006457A - Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13. - Google Patents

Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.

Info

Publication number
MX2009006457A
MX2009006457A MX2009006457A MX2009006457A MX2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating
pathologies
fibrosis
Prior art date
Application number
MX2009006457A
Other languages
English (en)
Inventor
Lynne A Murray
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of MX2009006457A publication Critical patent/MX2009006457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos para tratar una condición o patología relacionada con fibrosis relacionada con IL-4 o IL-13, incluyendo composiciones, formulaciones, métodos y dispositivos terapéuticos.
MX2009006457A 2006-12-15 2007-12-13 Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13. MX2009006457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87010506P 2006-12-15 2006-12-15
PCT/US2007/087346 WO2008076784A2 (en) 2006-12-15 2007-12-13 Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies

Publications (1)

Publication Number Publication Date
MX2009006457A true MX2009006457A (es) 2009-08-25

Family

ID=39536976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006457A MX2009006457A (es) 2006-12-15 2007-12-13 Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.

Country Status (13)

Country Link
US (1) US20100008914A1 (es)
EP (1) EP2125037A2 (es)
JP (1) JP2010513301A (es)
KR (1) KR20090101924A (es)
CN (1) CN101646465A (es)
AU (1) AU2007334022A1 (es)
BR (1) BRPI0721170A2 (es)
CA (1) CA2672878A1 (es)
EA (1) EA200970588A1 (es)
IL (1) IL199347A0 (es)
MX (1) MX2009006457A (es)
WO (1) WO2008076784A2 (es)
ZA (1) ZA200904921B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
AR085911A1 (es) * 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
ATE503233T1 (de) * 2002-06-14 2011-04-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind

Also Published As

Publication number Publication date
WO2008076784A3 (en) 2008-10-23
CA2672878A1 (en) 2008-06-26
JP2010513301A (ja) 2010-04-30
EA200970588A1 (ru) 2009-12-30
ZA200904921B (en) 2010-09-29
KR20090101924A (ko) 2009-09-29
BRPI0721170A2 (pt) 2014-03-18
AU2007334022A1 (en) 2008-06-26
US20100008914A1 (en) 2010-01-14
WO2008076784A2 (en) 2008-06-26
EP2125037A2 (en) 2009-12-02
CN101646465A (zh) 2010-02-10
IL199347A0 (en) 2010-03-28

Similar Documents

Publication Publication Date Title
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL254184B (en) Compositions and methods for treating collagen-mediated diseases
SI1948234T1 (sl) Sestavki in postopki za zdravljenje in preprečevanje fibrotičnih, vnetnih in neovaskularizacijskih stanj
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
MY161415A (en) A homeopathic formulation
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IN2012DN02471A (es)
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
TW200716088A (en) Formulations and methods for treating amyloidosis
MX2009006457A (es) Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.
EP1957509A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
UA94737C2 (ru) Соединения на основе имидазола, композиция, которая их содержит, и их применение
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности
HK1105313A (en) Methods and compositions for the treatment of lipid-associated disorders

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal